For example, EZH2 inhibition enhances antigen presentation and antitumor immunity in head and neck cancer, whereas when treated in an anti-PD1 resistant model, it showed improved efficacy of anti-PD1 therapy [107]. Here, PDCD1 is linked to head and neck cancer.